Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid in Pediatric Bone Tumor Surgery
NCT05024253Phase 3Completed
- Sponsor
- Children's Cancer Hospital Egypt 57357
- Start
- Aug 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tranexamic acid in Ewing sarcoma and osteosarcoma (OS) (2 arms), sponsored by Children's Cancer Hospital Egypt 57357. Primary endpoints: Intraoperative blood loss and Postoperative blood loss. Started Aug 2021; status: completed.
02
Drugs
tranexamic acid
03
Conditions
Ewing sarcomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT05024253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024253.